| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA Date example | PDUFA | — | Subscribe to access the data. | Peptides | Hematologic System | ||
PDUFA Date example | PDUFA | — | Subscribe to access the data. | Peptides | Hematologic System | ||
PDUFA Date example | PDUFA | — | Subscribe to access the data. | Peptides | Hematologic System |
Recent Updates
Recently added Catalysts
Protagonist Therapeutics, Inc.$129.89
-1.53 (-1.16%)
C 49Pipeline Score Richly Valued Pharma · Commercial
Market Cap
6.38 B
EPS
-1.80
P/E Ratio
-
Value Trade
54.59 M
SEC Financials
Q1 2026Dilution Risk
Revenue
56.37 M
R&D Expenses
46.74 M
Operating CF
-48.94 M
Total Assets
697.46 M
Total Liabilities
41.99 M
Equity
655.47 M
D/E Ratio
12,345
-4.83 %
Week
-6.8 %
1 Month
19.13 %
3 Month
17.75 %
6 Month
197.96 %
5 Year
726.58 %
All Time
Cash Data
Cash Position
547.79 M
Monthly Burn
16.31 M
Runway
31.4 mo
Burn Trend
SEC Filing
May 5, 2026
Overview
Volume
541.06 K
52 Week Range
45.28 - 107.84
% held by Insiders
5.1 %
% held by Institutions
120.14 %
Enterprise Value
5.84 B
Total Shares
63.79 M
Short %
12.6 %
Float Shares
59.71 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Protagonist Therapeutics, Inc.
372Total events
13Upcoming
106Tier-1 (high impact)
2016 – 2028Coverage
Upcoming catalysts 2
TBD
T1PDUFA Date
Subscribe to view catalyst details
TBD
T2Trial Initiation
Subscribe to view catalyst details
Event history 2
TBD
◆Oral PresentationPresentation
Subscribe to view catalyst details
TBD
◆Oral PresentationPresentation
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
C49
Pipeline Score $879M
Pipeline ValueRichly Valued
Valuation Signal7
Drugs Scored0.1x
rNPV / MCap Top 73%
Small Cap (rank 247 of 912)
Percentile RankProtagonist Therapeutics, Inc. carries a moderate pipeline score (49/100), with $1.4B risk-adjusted pipeline value, led by Rusfertide in Polycythemia Vera (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rusfertide Small molecule | Polycythemia Vera | Phase 3 | NCT05210790 | 68% | $729M | ACTIVE NOT_RECRUITING | 339 | VERY_FAST | B (62) | Jun 1, 2027 | MODERATE_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
ICOTYDE | moderate-to-severe plaque psoriasis | Phase 3 | 2026-03-30 | Rates of PASI 100 increased from Week 24 to Week 52; Nearly 60% of adolescents treated with ICOTYDE achieved completely clear skin at one year; 86% achieved PASI 90; 92% maintaining that response from Week 24 to Week 52 Read More | Protagonist Announces Presentation of One-Year Phase 3 Data for ICOTYDE(TM) in Moderate-to-Severe Plaque Psoriasis at the 2026 American Academy of Dermatology (AAD) Annual Meeting Read More | |
ICOTYDE | moderate-to-severe plaque psoriasis | Phase 3 | 2026-03-30 | Rates of PASI 100 increased from Week 24 to Week 52; Nearly 60% of adolescents treated with ICOTYDE achieved completely clear skin at one year; 86% achieved PASI 90; 92% maintaining that response from Week 24 to Week 52 Read More | Protagonist Announces Presentation of One-Year Phase 3 Data for ICOTYDE(TM) in Moderate-to-Severe Plaque Psoriasis at the 2026 American Academy of Dermatology (AAD) Annual Meeting Read More | |
ICOTYDE | moderate-to-severe plaque psoriasis | Phase 3 | 2026-03-30 | Rates of PASI 100 increased from Week 24 to Week 52; Nearly 60% of adolescents treated with ICOTYDE achieved completely clear skin at one year; 86% achieved PASI 90; 92% maintaining that response from Week 24 to Week 52 Read More | Protagonist Announces Presentation of One-Year Phase 3 Data for ICOTYDE(TM) in Moderate-to-Severe Plaque Psoriasis at the 2026 American Academy of Dermatology (AAD) Annual Meeting Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in PTGX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
PTGX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
PTGX2026 European Hematology Association (EHA) Meeting
The article discusses findings from the Phase 3 VERIFY study on Rusfertide, highlighting its maintained efficacy and safety in patients with low-risk or high-risk Polycythemia Vera (PV). Additionally, it explores the drug's impact on PV-related symptoms and cytoreductive therapy use. Long-term results from related studies also indicate positive outcomes for phlebotomy-dependent patients.
Read more →PTGXProtagonist at the Jefferies Global Healthcare Conference
Protagonist's Head of HR, Carena Spivey, highlighted the company's commitment to diversity and inclusion at the Jefferies Global Healthcare Conference. With 65% of employees from underrepresented ethnic communities and 51% being women, Protagonist actively tracks its progress in fostering a diverse workplace. The company promotes a supportive culture that encourages open dialogue and innovation.
Read more →PTGXCorporate Presentation
Protagonist highlights its commitment to diversity and inclusion in the workplace, showcasing significant statistics such as 65% of employees from underrepresented communities and 51% being women. The company believes that a diverse culture is essential for innovation and success. Protagonist fosters a supportive environment that encourages employee growth and the expression of diverse viewpoints.
Read more →PTGXProtagonist Therapeutics to Participate in Two Investment Bank Conferences in June 2026
Protagonist Therapeutics announced its participation in two investment bank conferences in June 2026, where CEO Dinesh V. Patel will engage in fireside chats. The conferences include the Jefferies Global Healthcare Conference in New York and the Goldman Sachs Annual Global Healthcare Conference in Miami. The company also highlighted its successful product ICOTYDE, which is now approved for plaque psoriasis treatment.
Read more →PTGXProtagonist Reports First Quarter 2026 Financial Results and Provides Corporate Update
Protagonist Therapeutics reported strong financial results for Q1 2026, highlighted by the FDA approval of ICOTYDE for moderate-to-severe plaque psoriasis, which triggered a $50 million milestone payment. The company also announced that the NDA for rusfertide was accepted and granted Priority Review by the FDA. Protagonist's robust cash position of $620 million is expected to sustain operations through at least 2028, supporting ongoing clinical programs and future milestones.
Read more →PTGXProtagonist Therapeutics Reports Granting of Inducement Awards - April 16, 2026
Protagonist Therapeutics announced the issuance of inducement awards to two new employees, which includes options and restricted stock units. The awards were granted under the company's Amended and Restated Inducement Plan and are intended to incentivize new hires. Protagonist is known for its peptide technology platform and has several drug candidates in development, including ICOTYDE and rusfertide.
Read more →PTGXProtagonist Announces Presentation of One-Year Phase 3 Data for ICOTYDE(TM) in Moderate-to-Severe Plaque Psoriasis at the 2026 American Academy of Dermatology (AAD) Annual Meeting
Protagonist Therapeutics presented one-year Phase 3 data for ICOTYDE at the AAD 2026 meeting, showcasing its effectiveness in achieving skin clearance for moderate-to-severe plaque psoriasis. The results support ICOTYDE's profile as a differentiated oral therapy with a favorable safety profile. The data indicate sustained efficacy and a strong safety record, reinforcing the potential of Protagonist's peptide discovery platform.
Read more →PTGXCORRECTION: Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Protagonist Therapeutics reported its financial results for Q4 and full year 2025, highlighting the submission of an NDA for rusfertide to the FDA. The company anticipates significant growth driven by upcoming regulatory decisions and has expanded its pre-clinical pipeline. However, it also reported a decrease in collaboration revenue and a net loss for the year.
Read more →PTGXProtagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Protagonist Therapeutics reported its financial results for Q4 and full year 2025, highlighting the submission of an NDA for rusfertide to the FDA. The company anticipates significant growth driven by regulatory milestones and has successfully completed multiple Phase 3 studies. However, it also faced a notable decrease in collaboration revenue and reported a net loss for the year.
Read more →PTGXCOMPANY OVERVIEW Dinesh V. Patel, Ph.D. President & CEO
Protagonist Therapeutics, Inc. is advancing its clinical pipeline with noteworthy programs focused on immunology, particularly icotrokinra and rusfertide, which are approaching important regulatory milestones. Collaborations with Johnson & Johnson and Takeda are positioned to drive potential financial benefits through milestone payments and royalties. The company's diversified strategy and innovative candidates indicate a strong focus on addressing unmet medical needs in inflammation, hematology, and metabolic diseases.
Read more →PTGXProtagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera
Protagonist Therapeutics and Takeda presented new 52-week data from the Phase 3 VERIFY study on rusfertide for polycythemia vera at the ASH Annual Meeting. The results indicate that 61.9% of patients maintained absence of phlebotomy eligibility, demonstrating the treatment's durability and safety. The findings suggest rusfertide could become a new standard of care for patients with PV.
Read more →PTGXProtagonist Reports Third Quarter 2025 Financial Results and Provides Corporate Update Following the NDA submission for icotrokinra treatment of adults and adolescents with moderate to severe plaque psoriasis to the U.S.
Protagonist Therapeutics reported its financial results for Q3 2025, highlighting a cash position of $678.8 million that can sustain operations through at least the end of 2026. The company has submitted NDAs for its psoriasis treatment icotrokinra to both the FDA and EMA. Significant advancements are noted in collaborative programs, particularly with Johnson & Johnson in expanding the ICONIC program and upcoming presentations at the ASH meeting. However, the company faces ongoing losses, with a reported net loss of $39.3 million for the quarter.
Read more →PTGXProtagonist Reports Second Quarter 2025 Financial Results and Provides Corporate Update NDA for icotrokinra for the treatment of adults and adolescents 12 years of age and older with moderate to severe plaque psoriasis (
Protagonist Therapeutics reported its second-quarter financial results for 2025, indicating significant corporate advancements, including the submission of a New Drug Application (NDA) for icotrokinra, aimed at treating moderate to severe plaque psoriasis. The company highlighted promising data from ongoing trials and upcoming presentations that may bolster its pipeline. However, financial results showed a rising net loss and a considerable decline in collaboration revenue compared to the previous year. As it approaches further NDA filings, Protagonist's strong cash position could be crucial for its continued development efforts.
Read more →PTGX▼ -5.1%on this news
Protagonist Reports First Quarter 2025 Financial Results and Provides Corporate Update Positive top line results from rusfertide Phase 3 VERIFY trial in polycythemia vera (PV) announced; full data selected for oral prese
Protagonist Therapeutics reported its first quarter 2025 financial results, highlighting positive outcomes from its rusfertide Phase 3 VERIFY trial in polycythemia vera. The results will be presented at the ASCO plenary session on June 1st. The company also provided updates on its ongoing studies with icotrokinra, which showed favorable results in ulcerative colitis. Despite a reported net loss, Protagonist's cash reserves are expected to support its operations through at least 2028.
Read more →PTGX▲ +45.9%on this news
Icotrokinra Clinical Study Results Demonstrate its Potential to Shift Treatment Paradigm and Set a New Standard for Treatment in Plaque Psoriasis Nearly half of patients with moderate-to-severe plaque psoriasis (PsO) tre
Protagonist Therapeutics announced promising results from the Phase 3 ICONIC studies for icotrokinra (JNJ-2113), showing that nearly 50% of patients with moderate-to-severe plaque psoriasis achieved completely clear skin at Week 24. The studies demonstrated that icotrokinra was superior to deucravacitinib, indicating its potential to change the treatment landscape for psoriasis. These results also set the stage for the upcoming ICONIC-ASCEND study, which will conduct a head-to-head comparison between icotrokinra and the injectable ustekinumab. Icotrokinra is aimed at providing a more convenient oral treatment option for patients.
Read more →PTGXProtagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera Study met the primary endpoint, with a significantly higher proportion of c
Protagonist Therapeutics and Takeda announced positive topline results from the Phase 3 VERIFY study for rusfertide in patients with polycythemia vera. The study met its primary endpoint and all key secondary endpoints, showcasing the drug's potential efficacy. Rusfertide, a hepcidin mimetic, has received both Orphan Drug and Fast Track designations from the FDA, further facilitating its development. The promising results position rusfertide as a potential breakthrough for patients with uncontrolled hematocrit levels.
Read more →PTGXProtagonist Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update $165.0 million icotrokinra (formerly JNJ-2113) milestone earned in Q4 2024, received in January 2025 PN-881, a potenti
Protagonist Therapeutics has reported its financial results for Q4 and the full year 2024, highlighting a milestone payment of $165 million earned in Q4 from its collaboration on icotrokinra. The company maintains a solid financial position, with cash and equivalents totaling $559.2 million, anticipated to support operations through 2028. Key clinical trial results for both rusfertide and icotrokinra are expected in March 2025, alongside the advancement of the oral IL-17 receptor antagonist PN-881 into clinical studies.
Read more →PTGXProtagonist announces positive topline results from Phase 3 ICONIC studies of icotrokinra (JNJ-2113) in plaque psoriasis, a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor
Protagonist Therapeutics announced positive topline results from two pivotal Phase 3 studies, ICONIC-LEAD and ICONIC-TOTAL, evaluating icotrokinra (JNJ-2113) in patients with moderate to severe plaque psoriasis. The drug met its co-primary endpoints, demonstrating significant skin clearance compared to placebo. Protagonist has earned $165 million in milestone payments from Johnson & Johnson under an amended agreement, reinforcing its collaboration and progress in the pipeline. Upcoming clinical studies and potential regulatory submissions are anticipated in 2025.
Read more →PTGXProtagonist Reports Third Quarter 2024 Financial Results and Provides Corporate Update Top line results for JNJ-2113 Phase 3 ICONIC-LEAD and Phase 3 ICONIC-TOTAL clinical trials in patients with moderate to severe psoria
Protagonist Therapeutics has reported its financial results for the third quarter of 2024, including a cash position of $583.3 million, which is expected to sustain operations through 2027. The company anticipates significant clinical trial results for its drug candidates, JNJ-2113 and rusfertide, in late 2024 and early 2025. Despite a net loss reported this quarter, the upcoming results from critical trials may impact the company’s trajectory positively. Protagonist is also preparing for the nomination of a new oral IL-17 peptide antagonist in Q4 2024.
Read more →PTGXProtagonist Reports Second Quarter 2024 Financial Results and Provides Corporate Update JNJ-2113 Phase 3 ICONIC-LEAD and Phase 3 ICONIC-TOTAL clinical trials in moderate-to-severe plaque psoriasis expected to complete th
Protagonist Therapeutics (PTGX) announced its financial results for Q2 2024, revealing significant progress in its clinical trials, particularly for JNJ-2113 and rusfertide. The company anticipates key trial results in Q4 2024 and Q1 2025, which could bolster its position in the biopharmaceutical market. With a cash reserve of $595.4 million, Protagonist expects to sustain operations through the end of 2027. Despite a reduction in net loss, the company acknowledges ongoing risks that could impact its future performance.
Read more →PTGXProtagonist Reports First Quarter 2024 Financial Results and Provides Corporate Update Entered into a worldwide license and collaboration agreement for rusfertide with Takeda; Cash runway extended through Q4 2027 1 Enrol
Protagonist Therapeutics reported its first quarter financial results for 2024, highlighting a successful partnership with Takeda for the development of rusfertide. The company's strong financial position is reinforced with a cash runway extended through Q4 2027, aided by a $300 million upfront payment from Takeda. Additionally, both Phase 3 trials of JNJ-2113 for psoriasis have completed enrollment, and the company anticipates announcing a new development candidate from its oral IL-17 program by the end of 2024. Recent positive outcomes from Phase 2 studies bolster expectations around JNJ-2113 continuing as a leading treatment in immunology.
Read more →PTGXProtagonist Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update Worldwide collaboration agreement executed with Takeda Pharmaceuticals, including a $300 million upfront payment for r
Protagonist Therapeutics reported its fourth quarter and full year financial results for 2023, highlighting a successful collaboration with Takeda Pharmaceuticals. The agreement includes a $300 million upfront payment for the development of rusfertide, aimed at treating polycythemia vera and other hematological conditions. Notably, Protagonist achieved $60 million in milestone revenues for Q4 related to JNJ-2113, while also making progress in its ongoing clinical trials and expanded research efforts. Despite these achievements, the company recorded a substantial net loss, indicating the financial pressures experienced during the year.
Read more →PTGXJP Morgan 42 nd Annual Healthcare Conference Dinesh V.
Protagonist Therapeutics President & CEO Dinesh V. Patel presented at the JP Morgan 42nd Annual Healthcare Conference, outlining the company's forward-looking strategies and updates on its clinical trials. The company is focused on developing Rusfertide, a hepcidin mimetic designed to address the unmet needs in treating Polycythemia Vera. Current clinical data suggests promise in managing hematocrit levels effectively, with a robust pipeline targeting multiple indications in hematology. The presentation emphasized the potential of their peptide-based therapies alongside ongoing collaborations with key partners.
Read more →PTGXProtagonist Reports Third Quarter 2023 Financial Results and Provides Corporate Update Five rusfertide abstracts accepted for oral and poster presentations at the 65 th ASH Annual Meeting and Exposition (ASH2023) Positiv
Protagonist Therapeutics (PTGX) reported its third quarter 2023 financial results, highlighting noteworthy advancements in its clinical development programs. The company announced that positive results from the Phase 2b FRONTIER 1 study of JNJ-2113, an oral IL-23 receptor antagonist, have led to the initiation of multiple Phase 3 studies for psoriasis and ulcerative colitis. Additionally, rusfertide is advancing in its Phase 3 VERIFY study for polycythemia vera, with presentations scheduled at the upcoming ASH2023 Annual Meeting. However, Protagonist continues to experience significant financial losses.
Read more →PTGXProtagonist Reports Second Quarter 2023 Financial Results and Provides Corporate Update Positive topline results from the Phase 2b FRONTIER 1 study of JNJ-2113 (formerly PN-235), the first and only IL-23 receptor antagon
Protagonist Therapeutics reported second quarter 2023 financial results, highlighting positive topline data from the Phase 2b FRONTIER 1 trial of JNJ-2113, an oral IL-23 receptor antagonist for plaque psoriasis. This promising data has led to plans for a Phase 3 study in psoriasis and a Phase 2b study in ulcerative colitis. The company also presented positive results from the Phase 2 REVIVE study of rusfertide for polycythemia vera at a major conference. Despite achieving significant clinical milestones, Protagonist recorded a net loss of $38.46 million for the quarter.
Read more →PTGXProtagonist Reports First Quarter 2023 Financial Results and Provides Corporate Update Announced positive topline results from the Phase 2b FRONTIER 1 study of JNJ-2113 (formerly PN-235), a first-in-class oral peptide fo
Protagonist Therapeutics reported encouraging financial results for Q1 2023, highlighting positive topline findings from the Phase 2b FRONTIER 1 study of JNJ-2113, a novel oral peptide for treating moderate to severe plaque psoriasis. Additionally, the company announced successful data from the Phase 2 REVIVE study of rusfertide, indicating significant efficacy in polycythemia vera. Protagonist also completed a public offering, securing $108.1 million to extend its cash runway through 2025, which will support ongoing clinical trials. Despite the positive developments, the company noted a substantial net loss for the quarter and an increasing accumulated deficit.
Read more →PTGXProtagonist Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update Positive results from the Phase 2b FRONTIER 1 study of JNJ-2113 (formerly PN-235) in moderate-to-severe p
Protagonist Therapeutics reported positive financial results for 2022 and provided updates on its clinical studies. Notably, the Phase 2b FRONTIER 1 study of JNJ-2113 showed promising outcomes for treating moderate-to-severe plaque psoriasis. Additionally, the REVIVE study demonstrated significant efficacy with the rusfertide treatment in polycythemia vera patients, achieving its primary endpoint. Protagonist is also progressing towards a Phase 3 study and a potential pre-commercial launch for rusfertide.
Read more →PTGXProtagonist Reports Third Quarter 2022 Financial Results and Provides Corporate Update Continued execution of Phase 3 VERIFY study of rusfertide in polycythemia vera Arturo Molina, M.D., M.S. named Chief Medical Officer,
Third Quarter 2022 Financial Results and Provides Corporate Update Continued execution of Phase 3 VERIFY study of rusfertide in polycythemia vera Arturo Molina, M.D., M.S. named Chief Medical Officer, providing medical, clinical development, and strategic leadership to the ru
Read more →PTGXProtagonist Reports Second Quarter 2022 Financial Results and Provides Corporate Update Continued focus on Phase 3 VERIFY study of rusfertide in polycythemia vera (PV) Presented new, positive data from Phase 2 REVIVE stu
Reports Second Quarter 2022 Financial Results and Provides Corporate Update focus on Phase 3 VERIFY study of rusfertide in polycythemia vera (PV) new, positive data from Phase 2 REVIVE study of rusfertide in PV at the 2022 ASCO Annual Meeting and the EHA2022 Congress cash pos
Read more →PTGXProtagonist Reports First Quarter 2022 Financial Results and Provides Corporate Update Initiated Phase 3 VERIFY study of rusfertide in polycythemia vera, reaffirming rusfertide in PV as the Company's primary point of foc
Reports First Quarter 2022 Financial Results and Provides Corporate Update Phase 3 VERIFY study of rusfertide in polycythemia vera, reaffirming rusfertide in PV as the Company's primary point of focus topline results from the Phase 2 IDEAL study of PN-943 in ulcerative colitis
Read more →PTGXProtagonist Therapeutics Announces Topline Data from Phase 2 IDEAL Study of PN-943 in Ulcerative Colitis PN-943 achieved 27.5% clinical remission with a delta of 13% versus placebo, with strong concordance across all key
Protagonist Therapeutics Announces Topline Data from Phase 2 IDEAL Study of PN-943 in Ulcerative Colitis PN-943 achieved 27.5% clinical remission with a delta of 13% versus placebo, with strong concordance across all key proxies including histological and endoscopic endpoints
Read more →PTGX▲ +8.3%on this news
COMPANY OVERVIEW Dinesh V. Patel, PhD | President & CEO April 2022 Forward - looking Statements 2 This presentation and the accompanying oral presentation contain forward - looking statements made pursuant to the safe ha
1 COMPANY OVERVIEW Dinesh V. Patel, PhD | President & CEO April 2022 Forward - looking Statements 2 This presentation and the accompanying oral presentation contain forward - looking statements made pursuant to the safe harbor pro visions of the Private Securities Litigation Ref
Read more →PTGXProtagonist Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Update Pivotal Phase 3 VERIFY study of rusfertide in polycythemia vera expected to initiate in Q1 2022 Topline results fr
Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Update Phase 3 VERIFY study of rusfertide in polycythemia vera expected to initiate in Q1 2022 results from the Phase 2 IDEAL study of PN-943 in ulcerative colitis expected in Q2 2022 has b
Read more →PTGXProtagonist Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update Resumption of the Phase 2 study of rusfertide in polycythemia vera now underway, following swift removal of the FDA clin
Protagonist Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update Resumption of the Phase 2 study of rusfertide in polycythemia vera now underway, following swift removal of the FDA clinical hold concept data for rusfertide in hereditary hemo
Read more →PTGX▼ -62%on this news
Protagonist Therapeutics Reports FDA Clinical Hold on Rusfertide Clinical Development Program
Therapeutics Reports FDA Clinical Hold on Rusfertide Clinical Development Program Calif., September 17, 2021-Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced the receipt of a verbal communication from the U.S. Food and Drug Administ
Read more →PTGXProtagonist Therapeutics Reports Second Quarter 2021 Financial Results and Recent Company Progress
Therapeutics Reports Second Quarter 2021 Financial Results and Recent Company Progress NEWARK, Calif., August 4, 2021-Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today reported its financial results for the second quarter ended June 30, 2021,
Read more →PTGXPN - 943 PTG - 200 PN - 232 PN - 235 rusfertide (PTG - 300) PTG - 100 Dinesh V. Patel, PhD President & CEO June 2021 COMPANY OVERVIEW 1 Forward - looking Statements 2 This presentation and the accompanying oral presentat
PN - 943 PTG - 200 PN - 232 PN - 235 rusfertide (PTG - 300) PTG - 100 Dinesh V. Patel, PhD President & CEO June 2021 COMPANY OVERVIEW 1 Forward - looking Statements 2 This presentation and the accompanying oral presentation contain forward - looking statements made pursuant to t
Read more →PTGXProtagonist Reports First Quarter 2021 Financial Results and Provides Corporate Update
Reports First Quarter 2021 Results and Provides Corporate Update NEWARK, California, May 4, 2021 - Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") today reported financial results for the first quarter of 2021 ended March 31, 2021 and provided a corpo
Read more →PTGXProtagonist Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Update -- Regulatory guidance anticipated in the first half of 2021 for registrational clinical development plan of inves
Protagonist Therapeutics Reports Fourth Quarter and Full Results and Corporate Update -- Regulatory guidance anticipated in the first half of 2021 for registrational clinical development plan of investigational drug, rusfertide (PTG-300), for polycythemia -- Company expects t
Read more →PTGXProtagonist Therapeutics Reports Third Quarter Financial Results and Provides Corporate Update -- Updated Phase 2 results for hepcidin mimetic PTG-300 in polycythemia vera accepted for oral presentation at the ASH Annual
Protagonist Therapeutics Reports Third Quarter Financial Results and Provides Corporate Update -- Updated Phase 2 results for hepcidin mimetic PTG-300 in polycythemia vera accepted for oral presentation at the ASH Annual Meeting in December 2020 -- -- PTG-300 received Europea
Read more →PTGXPTG - 300 Opportunity Update Dinesh V. Patel, PhD President & CEO 1
PTG - 300 Opportunity Update Dinesh V. Patel, PhD President & CEO 1 September 11, 2020 2 Forward Looking Statements This presentation contains forward - looking statements of Protagonist Therapeutics, Inc . (Protagonist) that involve substantial risks and uncertainties . All sta
Read more →PTGXProtagonist Therapeutics Reports Second Quarter Financial Results and Provides Corporate Update -- Company to host webinar highlighting the PTG-300 program market opportunity in polycythemia vera -- -- PTG-300 received U
Therapeutics Reports Second Quarter Financial Results and Provides Corporate Update Company to host webinar highlighting the PTG-300 program market opportunity in polycythemia vera -- PTG-300 received U.S. Food and Drug Administration (FDA) Orphan Drug Designation for the treat
Read more →PTGXProtagonist Therapeutics Reports First Quarter Financial Results and Provides Corporate Update -- Company selects the polycythemia vera indication for pivotal development of PTG-300 based on robust clinical responses --
Therapeutics Reports First Quarter Financial Results and Provides Corporate Update Company selects the polycythemia vera indication for pivotal development of PTG-300 based on robust clinical responses -- Revised and focused development plans now provide sufficient capital to f
Read more →PTGXProtagonist Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results -- Therapeutic candidate PTG-300 under evaluation in Phase 2 proof of concept studies in multiple blood disorder indications -- -- Two
Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results Therapeutic candidate PTG-300 under evaluation in Phase 2 proof of concept studies in multiple blood disorder indications -- Two differentiated, orally administered candidates PTG-200 and PN-943 in clinica
Read more →PTGXProtagonist Therapeutics Announces Preliminary Phase 2 Results with Hepcidin Mimetic PTG-300 in the Treatment of Transfusion Dependent Beta-Thalassemia Dose-related reductions in serum iron and transferrin saturation lev
Protagonist Therapeutics Announces Preliminary Phase 2 Results with Hepcidin Mimetic PTG-300 in the Treatment of Transfusion Dependent Beta-Thalassemia Dose-related reductions in serum iron and transferrin saturation levels provide first evidence of pharmacodynamic effects in pa
Read more →PTGXProtagonist Therapeutics Reports Third Quarter 2019 Financial Results Preliminary Phase 2 results for hepcidin mimetic PTG-300 in beta-thalassemia are expected in the fourth quarter of 2019 Company sponsored Phase 2 stud
Protagonist Therapeutics Reports Third Quarter 2019 Financial Results Preliminary Phase 2 results for hepcidin mimetic PTG-300 in beta-thalassemia are expected in the fourth quarter of 2019 Company sponsored Phase 2 study of PTG-300 in hereditary hemochromatosis and investigato
Read more →PTGXProtagonist Therapeutics Reports Second Quarter 2019 Financial Results Initial Phase 2 results for hepcidin mimetic PTG-300 in beta-thalassemia are expected in the fourth quarter of 2019 Phase 2 study of PTG-300 in polyc
Protagonist Therapeutics Reports Second Quarter 2019 Financial Results Initial Phase 2 results for hepcidin mimetic PTG-300 in beta-thalassemia are expected in the fourth quarter of 2019 Phase 2 study of PTG-300 in polycythemia vera expected to begin in the third quarter of 201
Read more →PTGXProtagonist Therapeutics Reports First Quarter 2019 Financial Results PTG-200 collaboration agreement with Janssen Biotech expanded to include second generation oral IL-23 receptor antagonists; expanded agreement trigger
Protagonist Therapeutics Reports First Quarter 2019 Financial Results PTG-200 collaboration agreement with Janssen Biotech expanded to include second generation oral IL-23 receptor antagonists; expanded agreement triggers $25 million milestone payment to Protagonist Protagonist
Read more →PTGXProtagonist Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results Preliminary results from the Phase 2 TRANSCEND study of the hepcidin mimetic PTG-300 for the treatment of beta thalassemia expected in
Protagonist Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results Preliminary results from the Phase 2 TRANSCEND study of the hepcidin mimetic PTG-300 for the treatment of beta thalassemia expected in the second half of 2019 U.S. Investigational New Drug (IN
Read more →PTGXProtagonist Therapeutics Announces New Development Candidate PN-10943 for the Treatment of Inflammatory Bowel Disease Oral, gut-restricted alpha-4-beta-7 integrin antagonist peptide PN-10943 has demonstrated greater pote
Protagonist Therapeutics Announces New Development Candidate PN-10943 for the Treatment of Inflammatory Bowel Disease Oral, gut-restricted alpha-4-beta-7 integrin antagonist peptide PN-10943 has demonstrated greater potency and target engagement in preclinical studies as compare
Read more →PTGXProtagonist Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update C linical, endoscopic, histologic and biomarker data are consistent with a dose-related clinical efficacy response of PT
Protagonist Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update Clinical, endoscopic, histologic and biomarker data are consistent with a dose-related clinical efficacy response of PTG-100 in the PROPEL Phase 2 ulcerative colitis study, provid
Read more →PTGXPTG-100, an Oral Gut-Restricted Peptide 47 Antagonist, Induces Clinical and Histologic Remission in Patients with Moderate to Severely Active Ulcerative Colitis William J Sandborn, Brian Bressler, Scott Lee, Raj Bhandari
PTG-100, an Oral Gut-Restricted Peptide 47 Antagonist, Induces Clinical and Histologic Remission in Patients with Moderate to Severely Active Ulcerative Colitis William J Sandborn, Brian Bressler, Scott Lee, Raj Bhandari, Bittoo Kanwar, Lucio Tozzi, Richard Shames, Geert D Haens,
Read more →PTGXProtagonist Therapeutics Reports Second Quarter 2018 Financial Results
Protagonist Therapeutics Reports Second Quarter 2018 Financial Results NEWARK, Calif., Aug. 7, 2018 -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported its financial results for the second quarter ended June 30, 2018. Protagonist continues to advance well-differentia
Read more →PTGXDinesh V. Patel, PhD President & CEO
Dinesh V. Patel, PhD President & CEO August 06, 2018 Conference Call CONFIDENTIAL PTG-100: Oral, 4 7-specific, GI-restricted, Targeted Therapy for IBD Randomized, double-blind, placebo-controlled adaptive parallel design 12 week induction study, q.d. dosing 2 Phase 2b PROPEL Stu
Read more →PTGXProtagonist Therapeutics Reports First Quarter 2018 Financial Results Newark, CA (
Protagonist Therapeutics Reports First Quarter 2018 Financial Results Newark, CA (May 9, 2018): Protagonist Therapeutics, Inc. (Nasdaq: PTGX) today reported its financial results for the first quarter ended March 31, 2018. Protagonist is continuing to build a broad and diverse
Read more →PTGXProtagonist Therapeutics Reports Fourth Quarter and Year-End 2017 Financial Results Protagonist to host conference call today at 1:30 pm PT/4:30 pm ET Newark, CA (
Protagonist Therapeutics Reports Fourth Quarter and Year-End 2017 Financial Results Protagonist to host conference call today at 1:30 pm PT/4:30 pm ET Newark, CA (March 7, 2018): Protagonist Therapeutics, Inc. (NASDAQ: PTGX) today reported its financial results for the fourth q
Read more →PTGXCOMPANY OVERVIEW Dinesh V. Patel, PhD President & CEO January 2018 Forward Looking Statements This presentation contains forward-looking statements of Protagonist Therapeutics, Inc. (Protagonist). All statements other th
COMPANY OVERVIEW Dinesh V. Patel, PhD President & CEO January 2018 Forward Looking Statements This presentation contains forward-looking statements of Protagonist Therapeutics, Inc. (Protagonist). All statements other than statements of historical facts contained in this present
Read more →PTGXProtagonist Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update Recent $60 Million Financing Enables Company to Push Pipeline Candidates Forward Newark, California (
Protagonist Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update Recent $60 Million Financing Enables Company to Push Pipeline Candidates Forward Newark, California (November 6, 2017): Protagonist Therapeutics, Inc. (NASDAQ: PTGX) today report
Read more →PTGXRISK FACTORS Investing in our common stock involves a high degree of risk. You should consider carefully the following risks before you invest in our common stock. If any of the following risks actually materializes, our
Investing in our common stock involves a high degree of risk. You should consider carefully the following risks before you invest in our common stock. If any of the following risks actually materializes, our operating results, future prospects, financial condition and liquidity c
Read more →PTGXProtagonist Therapeutics Reports Second Quarter 2017 Financial Results and Business Highlights
Protagonist Therapeutics Reports Second Quarter 2017 Financial Results and Business Highlights Worldwide co-development agreement with Janssen for PTG-200 brings $50M upfront and potentially up to $940M in milestones Q2 cash balance of $64.5M - Cash to middle of 2019 Newark, C
Read more →PTGXProtagonist Therapeutics Reports First Quarter 2017 Financial Results Milpitas, CA (
Protagonist Therapeutics Reports First Quarter 2017 Financial Results Milpitas, CA (May 10, 2017): Protagonist Therapeutics, Inc. (NASDAQ: PTGX) today reported its financial results for the first quarter ended Our R&D activities to have three different assets in clinical develo
Read more →PTGXProtagonist Therapeutics Reports Fourth Quarter and Year-End 2016 Financial Results - Phase 2b Trial Underway for PTG-100 in Ulcerative Colitis - PTG-200 & PTG-300 Expected to Enter the Clinic in 2017 Milpitas, CA (
Protagonist Therapeutics Reports Fourth Quarter and Year-End 2016 Financial Results - Phase 2b Trial Underway for PTG-100 in Ulcerative Colitis - PTG-200 & PTG-300 Expected to Enter the Clinic in 2017 Milpitas, CA (March 7, 2017): Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
Read more →PTGXProtagonist Therapeutics Reports Third Quarter 2016 Financial Results and Provides Corporate Update Upsized Initial Public Offering in August 2016, Raising Gross Proceeds of $93M Successful Completion of Phase 1 Study fo
Protagonist Therapeutics Reports Third Quarter 2016 Financial Results and Provides Corporate Update Milpitas, CA (November 14, 2016): Protagonist Therapeutics, Inc. (NASDAQ: PTGX) today reported its financial results for the quarter ended September 30, 2016 and provided an upd
Read more →Competitive Position
How PTGX ranks across every disease it competes inCompetitive Position is a premium feature
See how PTGX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial